[Histone deacetylase inhibitors in the treatment of hematological malignancies]

Related Experiment Video

Updated: May 30, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Richard Lemal1, Aurélie Ravinet, Cécile Moluçon-Chabrot

  • 1CHU Estaing, service d'hématologie clinique adulte, Clermont-Ferrand Cedex, France.

Bulletin Du Cancer
|August 11, 2011
PubMed

Insights

Histone deacetylases inhibitors (HDACi) are a promising epigenetic therapy for hematologic malignancies. These drugs restore tumor suppressor genes, showing anti-cancer activity and leading to FDA-approved treatments.

Area of Science:

  • Epigenetics and molecular oncology
  • Pharmacology of targeted therapies

Context:

  • Histone deacetylases inhibitors (HDACi) are an emerging class of epigenetic drugs.
  • HDACi are being investigated for their anti-tumoral effects in various cancers.
  • Two HDACi, vorinostat and romidepsin, are FDA-approved for refractory cutaneous T-cell lymphomas.

Purpose:

  • To review recent developments and current investigations of HDAC inhibitors.
  • To highlight the anti-neoplastic activity of HDACi in hematologic malignancies.
  • To discuss the molecular mechanisms of HDACi in cellular pathways.

Summary:

  • HDAC inhibitors modulate gene expression by targeting histone deacetylases, impacting tumor suppressor genes.
  • They exhibit anti-tumoral activity by influencing differentiation, proliferation, and survival pathways.
  • Preclinical and clinical data suggest efficacy across a range of hematologic cancers.

Impact:

  • HDACi represent a significant advancement in epigenetic cancer therapy.
  • Their application in hematology has led to approved treatments and holds promise for other blood cancers.
  • Ongoing research continues to explore the therapeutic potential of HDAC inhibitors.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...